Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit

Abstract Introduction Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by...

Full description

Saved in:
Bibliographic Details
Main Authors: Johnna Perdrizet, An Ta, Liping Huang, Warisa Wannaadisai, Aleksandar Ilic, Kyla Hayford, Ayman Sabra
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Infectious Diseases and Therapy
Subjects:
Pneumococcal conjugate vaccine
Pneumococcal disease
PCV20
Policymakers
Pediatric
National immunization program
Online Access:https://doi.org/10.1007/s40121-025-01108-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01108-3

Similar Items